Cointime update: Akeso’s shares fell more than 24% after the US Food and Drug Administration declined to approve the company’s first marketing application for ivonescimab, its oncology immunotherapy drug, in the United States. The drop followed the rejection of the China-based biotech’s bid to launch the drug in the US market.
Akeso Shares Plunge Over 24% After FDA Rejection of Ivonescimab
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
11m ago
Hong Kong’s Hang Seng closes down 0.91%; Zhipu jumps over 9%
46m ago
JPMorgan Keeps Zhipu at Overweight, HK$1,200 Target
51m ago
Morgan Stanley’s Wilson: Nvidia Q3 Results Broadly In Line, AI Still Worth Investing
1h ago
Nvidia beats estimates; analysts flag lingering uncertainty over outlook
2h ago
Binance to Launch USDT Perpetual Contracts for Six TradFi Assets
6h ago
Anthropic Expected to Price IPO Above Range at $80+ Per Share